Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Gain Therapeutics, Inc. (GANX)

Gain Therapeutics CFO Gianluca Fuggetta resigns; CEO Gene Mack named interim CFO

Neutral Impact 3 of 5 leadership Written later

Gain Therapeutics said its senior vice president of finance and principal financial officer, Gianluca Fuggetta, will resign effective September 30, 2026, to pursue other opportunities. The board appointed CEO Gene Mack as interim chief financial officer effective October 1, 2026, and the company is searching for a permanent replacement.

Key points

  • Gianluca Fuggetta gave notice on September 22, 2026; resignation effective September 30, 2026
  • Gene Mack, current President and CEO, appointed interim CFO effective October 1, 2026
  • Mack also assumes principal financial and principal accounting officer duties; his employment terms are unchanged
  • Company is conducting an ongoing search for a permanent principal financial officer

The filing

CompanyGain Therapeutics, Inc. (GANX)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:30 PM ET
Accession number0001104659-26-111391

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.